Ying Fu

Dr. Fu pursued her doctoral studies in Clinical Proteomics and Structural Biology at Xiangya Hospital of Central South University from September 2018 to June 2023, earning a Ph.D. degree. Since September 2025, she has been serving as an Associate Professor at the Key Laboratory of Oncoproteomics of the National Health Commission, Xiangya Hospital, Central South University. She has been serving as an Editorial Board Member of Frontiers in Molecular Medicine since December 2021. Dr. Fu has long been dedicated to cancer proteomics research, with a focus on comprehensive proteomic profiling of tumors and the discovery of small-molecule drug targets. As a key contributor to a sub-project of the National 973A Program, she pioneered the first systematic proteomic expression profile of human nasopharyngeal carcinoma, revealing its proteomic characteristics, potential molecular mechanisms, and therapeutic targets. In the field of chemical proteomics, using covalent FGFR inhibitors as a model, she integrated multi-omics approaches to systematically dissect the target interaction network in hepatocellular carcinoma, identifying novel drug targets and elucidating their mechanisms of action. As first or corresponding author, she has published 12 SCI-indexed papers (10 in JCR Q1) in leading journals including Advanced Science, Cell Death & Disease, Journal of Medicinal Chemistry, and Molecular & Cellular Proteomics. She holds one authorized national invention patent, has contributed to two monographs, and serves as the Principal Investigator of one project funded by the Young Scientists Fund of the National Natural Science Foundation of China (NSFC) and one project funded by the Natural Science Foundation of Hunan Province.

Selected publications:
1. Ying Fu, Dandan Zhu, Xiaojuan Chen, Lingzhi Qu, Ming Guo, Shuhong Zhang, Guangyu Xu, Zhuchu Chen, Maoyu Li, Yongheng Chen. Integrative Multi-Omics Approaches Reveal Selectivity Profiles and Molecular Mechanisms of FIIN-2, a Covalent FGFR Inhibitor. Advanced Science (Weinh), 2025, 12(14): e2412578.
2. Dandan Zhu, Zijian Zheng, Huixin Huang, Xiaojuan Chen, Shuhong Zhang, Zhuchu Chen, Ting Liu, Guangyu Xu, Ying Fu, Yongheng Chen*. Design, synthesis and biological evaluation of the activity-based probes for FGFR covalent inhibitor. European Journal of Medicinal Chemistry, 2025, 295: 117795. (Co-corresponding author)
3. Ying Fu, Xujun Liang, Xinming Yang, Jianping Liu, Huichao Huang, Pengfei Zhang, Shisheng Li, Dandan Zhu, Ye Zhang, Fang Peng, Yongheng Chen, Zhuchu Chen. Proteomics profiling reveals the molecular signatures and potential therapeutic targets of human nasopharyngeal carcinoma. Molecular & Cellular Proteomics, 2023, 22(6): 100567.
4. Jingzhi Li, Ming Guo, Lin Chen, Zhuchu Chen, Ying Fu, Yongheng Chen. Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma. Cell Death & Disease, 2024, 15(1): 35. (Co-corresponding author)
5. Yalan Deng, Liqing Lu, Xujun Liang, Jingzhi Li, Dandan Zhu, Huichao Huang, Ye Zhang, Xiangqian Zhang, Yongheng Chen, Xiaojin Liu, Ying Fu. DNA methylation-mediated silencing of Neuronatin promotes hepatocellular carcinoma proliferation through the PI3K-Akt signaling pathway. Life Sciences, 2023, 312: 121266. (Co-corresponding author)